Loading clinical trials...

COMPLETEDPHASE1

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.

NCT02970019•Sun Pharma Advanced Research Company Limited

View on ClinicalTrials.gov

Summary

This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Willing and able to give written, and dated, informed consent (or legally acceptable representative/impartial witness when applicable) and is available for the entire study
•2. Willing and able to comply with the scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions (in the Investigator's opinion), and be accessible for follow-up
•3. Male or female aged 18 to 65 years (both inclusive)
•4. Diagnosed with Parkinson's disease

Exclusion Criteria

•1. Clinical diagnosis of genetic form of Parkinson's disease, or drug-induced parkinsonism
•2. Diagnosis of Parkinson's disease Dementia (probable, possible)
•3. Presence of severe dyskinesias
•4. History of brain surgery for Parkinson's disease

Locations (5)

SPARC Site 03

Long Beach, California, United States

SPARC Site 05

Panorama City, California, United States

SPARC Site 01

DeLand, Florida, United States

SPARC Site 02

Orlando, Florida, United States

SPARC Site 04

Raleigh, North Carolina, United States

Key Dates

Start Date

March 30, 2017

Primary Completion Date

May 28, 2019

Completion Date

May 28, 2019

Last Updated

March 31, 2020

Enrollment

ACTUAL participants

Conditions

Parkinson Disease

Interventions

K0706

DRUG

Placebo

DRUG

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

NCT06692920

Parkinson Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 31, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Characterizing the Pathophysiological Role of the Pallido-thalamocortical Motor Pathway in Parkinson's Disease.

Montelukast in Parkinson Disease

Exercise for Cognitive Excellence in Parkinson's Disease

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations

The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients